The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
2016 ASCO EDUCATIONAL BOOK | asco.org/edbo
Capability and Performance
Sector Environmental Guidelines, Full technical Update
People younger than 20 years comprise 35% of the global population and 40% of the global population of least-developed nations. The number of children - neonates, infants, children, and adolescents up to 19 years of age - who need pediatric palliative care (PPC) each year may be as high as 21 millio...n. Another study found that almost 2.5 million children die each year with serious health related suffering and that more than 98% of these children are in low- and middle-income countries (LMICs) (3). While estimates differ, there is no doubt that there is an enormous need for prevention and relief of suffering among children - for PPC.
more
First edition, November 1997 | Revised July 2002
The essential medicines are those that meet the priority needs of the healthcare of the population. While reviewing the 5th edition of the essential Medicines, special attention focused on the health sector policy. Indeed, medicines play an important role in protecting, maintaining and restoring th...e peoples’ health and credibility of health facilities. Their availability is a fundamental aspect of primary health care as defined in different declarations including Alma-Ata of 1978.
more
2nd edition - Published in 2003, the first WHO/HAI medicine prices manual Medicine Prices – A
New Approach to Measurement Draft for field-testing provides a draft methodology and tools to conduct national medicine prices and availability surveys. This second edition of the survey manual has been... updated to reflect the wealth of practical
experience in conducting medicine prices and availability surveys garnered in the project’s first two phases.
more
International Journal of Basic & Clinical Pharmacology 5(6):2290-2294
DOI: 10.18203/2319-2003.ijbcp20164081
Document No. : FDA/SMC/SMD/GL-SMP/2015/05 |
These guidelines are for information, guidance and strict compliance by Marketing Authorization Holders and Local Representatives of regulated products to help in the continuous safety monitoring of products granted marketing authorization in Ghana.
During this work, a survey on essential medicines availability was conducted. This article was first written on this subject for sharing the poor financial availability of the essential medicines in the hospital and secondly, a call for an action to be taken in improving hospital pharmacies developm...ent in each hospital in Burkina Faso.
more
6th edition, 2010. | Published in collaboration with World Health Organisation and Clinton Health Access Initiative.
Cette première version des orientations evolutives relatives a la prise en charge clinique de la MVE contient quatre nouvelles recommandations concernant l’utilisation de traitements contre la MVE, y compris deux recommandations fortes en faveur de l’utilisation de thérapies à base d’antico...rps monoclonaux. Ce nouveau document est rédigé en vue d’accompagner des soins de support optimisés (oSoC) pour les procédures opérationnelles standards appliquees a la MVE (5, 6). Les orientations evolutives presentent des preuves de haute qualité concernant l’efficacite des traitements contre la MVE et les recommandations de l’OMS relatives leur utilisation.
more
The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il...lness is important.
The living guidance is available in both pdf format (via the ‘Download’ button) and via an online platform in both French and English, and is updated regularly as new evidence emerges.
This first version of the Clinical management for EVD living guidance contains four new recommendations regarding use of therapeutics for EVD, this includes two strong recommendations for the use of monoclonal antibody therapies. This new living guideline is written to accompany the optimized supportive care (oSoC) for EVD standard operating procedures (5, 6). The living guideline aims to summarize high quality evidence for EVD therapeutics and make recommendations for their use.
more
Estas directrices sustituyen a los anteriores documentos de política de la OMS sobre el manejo de la ILTB en las personas con la infección por el VIH, los contactos del hogar de personas con TB y otros grupos de riesgo. Las Directrices unificadas de la OMS sobre la tuberculosis: Tratamiento preven...tivo de la tuberculosis se elaboraron conforme a los requisitos del Comité de Examen de Directrices. El grupo de elaboración de las directrices (GDG, por su sigla en inglés) examinó la calidad de la evidencia más reciente disponible sobre la efectividad y los posibles perjuicios, así como la certeza de la evidencia, los valores y las preferencias, además de cuestiones de equidad, utilización de recursos, aceptabilidad y viabilidad de la aplicación al actualizar o formular nuevas recomendaciones y determinar su fuerza.
more